Available IPD datapackage for study 'MONARCH 2: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Fulvestrant With or Without Abemaciclib, a CDK4/6 Inhibitor, for Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer'
收藏DataCite Commons2025-09-12 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/dataPackages/PR00004521.1
下载链接
链接失效反馈官方服务：
资源简介：
The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib + fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant. For the endocrine naïve cohort, all participants will received abemaciclib + fulvestrant.
提供机构：
Vivli
创建时间：
2025-09-12
